Greater Manchester Cancer Treatment Summaries for Urology patients

Greater Manchester Cancer Treatment Summaries for Urology patients

It is the active involvement of patients and carers in how cancer services are commissioned, delivered, and evaluated.

Co-production is an equal and reciprocal relationship between a group of professionals and service users who have agreed to work in partnership to achieve a common goal.

People affected by cancer and healthcare professionals will be equal partners in the codesign and improvement of cancer services at Greater Manchester Cancer

The importance of User Involvement • Macmillan have funded the User Involvement programme for 4 yrs • We work within a co-produced UI Framework and principles: • Involve – opportunities, recruit, communicate • Support – staffing, pay expenses, 1: 1 or group support

Culture of User Involvement • That said … we can’t do this alone we need a culture which embraces User Involvement to ensure it becomes a meaningful part of our every day practice.

Greater Manchester Cancer GM Cancer Pathway Boards Acute Oncology Lung Pathway Director: Claire Mitchell Pathway Director: Matt Evison Brain and Central Nervous System Oesophago-gastric Pathway Director: Catherine Mc. Bain Breast Pathway Director: Mohammed Absar Children’s Pathway Director: Bernadette Brennan Colorectal Pathway Director: Sajal Rai Gynaecology Pathway Director: Lisa Barraclough Haemato-oncology Pathway Director: Jonathan Vickers Sarcoma Pathway Director: Amit Kumar Skin Pathway Director: John Lear Teenage and Young Adult Pathway Director: David Wright Urology Pathway Director: Satish Maddineni Systemic Therapies Pathway Director: Eleni Tholouli Director: Andrew Wardley Head and Neck Psychology Pathway Director: Susannah Penney Director: Padraig Mc. Donnell Hepato-pancreatic-biliary Supportive Care Management Pathway Director: Derek O’Reilly Genomics Pathway Director: Fiona Blackhall Director: Anne Marie Raftery

Urology Pathway Board

Urology treatment Summaries: Prostate - active surveillance, watchful wait, and the prostate hormone deprivation. Bladder - Non invasive, radical cystectomy Kidney – not yet complete

Note: it is now addressed to the patient and cc’d to GP

What does a treatment summary include? • Date and diagnosis • Summary of Management of your diagnosis and relevant dates • Treatment Aim • Possible Consequences of Continued Surveillance • Possible treatment side effects and / or late effects • Your Ongoing Management Plan • Other service referrals • Contacts for re-referrals or queries, incl out of hours for patient and GP • Alert Symptoms • Required GP actions in addition to GP Cancer Care Review

Mike Thorpe

PSA readings • After cancer treatment the PSA number is important, patients are given the responsibility to keep a check on their PSA

Appointments • Appointments for cancer patients in primary care – does your system give priority?

Thank you Any questions?